The Identification of -acting Factors That Regulate the Expression of via the Osteoarthritis Susceptibility SNP rs143383

English version České info

rs143383 is a C to T transition SNP located in the 5′untranslated region (5′UTR) of the growth differentiation factor 5 gene GDF5. The T allele of the SNP is associated with increased risk of osteoarthritis (OA) in Europeans and in Asians. This susceptibility is mediated by the T allele producing less GDF5 transcript relative to the C allele, a phenomenon known as differential allelic expression (DAE). The aim of this study was to identify trans-acting factors that bind to rs143383 and which regulate this GDF5 DAE. Protein binding to the gene was investigated by two experimental approaches: 1) competition and supershift electrophoretic mobility shift assays (EMSAs) and 2) an oligonucleotide pull down assay followed by quantitative mass spectrometry. Binding was then confirmed in vivo by chromatin immunoprecipitation (ChIP), and the functional effects of candidate proteins investigated by RNA interference (RNAi) and over expression. Using these approaches the trans-acting factors Sp1, Sp3, P15, and DEAF-1 were identified as interacting with the GDF5 5′UTR. Knockdown and over expression of the factors demonstrated that Sp1, Sp3, and DEAF-1 are repressors of GDF5 expression. Depletion of DEAF-1 modulated the DAE of GDF5 and this differential allelic effect was confirmed following over expression, with the rs143383 T allele being repressed to a significantly greater extent than the rs143383 C allele. In combination, Sp1 and DEAF-1 had the greatest repressive activity. In conclusion, we have identified four trans-acting factors that are binding to GDF5, three of which are modulating GDF5 expression via the OA susceptibility locus rs143383.

Vyšlo v časopise: The Identification of -acting Factors That Regulate the Expression of via the Osteoarthritis Susceptibility SNP rs143383. PLoS Genet 9(6): e32767. doi:10.1371/journal.pgen.1003557
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003557

Souhrn

Zdroje

1. BrandtKD, DieppeP, RadinE (2008) Etiopathogenesis of osteoarthritis. Rheum Dis Clin North Am 34: 531–559.

2. NüeschE, DieppeP, ReichenbachS, WilliamsS, IffS, et al. (2011) All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 342: d1165.

3. BurragePS, BrinckerhoffCE (2007) Molecular Targets in osteoarthritis: metalloproteinases and their inhibitors. Curr Drug Targets 8: 293–303.

4. SpectorTD, MacGregorAJ (2004) Risk factors for osteoarthritis: genetics. Osteoarthritis Cartilage 12: 39–44.

5. arcOGEN Consortium and arcOGEN Collaborators (2012) Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association scan. Lancet 380: 815–823.

6. MiyamotoY, MabuchiA, ShiD, KuboT, TakatoriY, et al. (2007) A functional polymorphism in the 5′UTR of GDF5 is associated with susceptibility to osteoarthritis. Nat Genet 39: 529–533.

7. SouthamL, Rodriguez-LopezJ, WilkinsJM, Pombo-SuarezM, SnellingS, et al. (2007) An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. Hum Mol Genet 16: 2226–2232.

8. ChapmanK, TakahashiA, MeulenbeltI, WatsonC, Rodriguez-LopezJ, et al. (2008) A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5′ UTR of GDF5 with osteoarthritis susceptibility. Hum Mol Genet 17: 1497–1504.

9. EgliR, SouthamL, WilkinsJM, LorenzenI, Pombo-SuarezM, et al. (2009) Functional analysis of the GDF5 regulatory polymorphism that is associated with OA susceptibility. Arthritis Rheum 60: 2055–2064.

10. Francis-WestPH, AbdelfattahA, ChenP, AllenC, ParishJ, et al. (1999) Mechanisms of GDF-5 action during skeletal development. Development 126: 1305–1315.

11. HottenGC, MatsumotoT, KimuraM, BechtoldRF, KronR, et al. (1996) Recombinant human growth/differentiation factor 5 stimulates mesenchyme aggregation and chondrogenesis responsible for the skeletal development of limbs. Growth Factors 13: 65–74.

12. ChhabraA, TsouD, ClarkRT, GaschenV, HunzikerEB, et al. (2003) GDF-5 deficiency in mice delays Achilles tendon healing. J Orthop Res 21: 826–835.

13. ChhabraA, ZijerdiD, ZhangJ, KlineA, BalianG, et al. (2005) BMP-14 deficiency inhibits long bone fracture healing: a biochemical, histologic, and radiographic assessment. J Orthop Trauma 19: 629–634.

14. ErlacherL, NgCK, UllrichR, KriegerS, LuytenFP (1998) Presence of cartilage-derived morphogenetic proteins in articular cartilage and enhancement of matrix replacement in vitro. Arthritis Rheum 41: 263–273.

15. RickertM, WangH, WielochP, LorenzH, SteckE, et al. (2005) Adenovirus-mediated gene transfer of growth and differentiation factor-5 into tenocytes and the healing rat Achilles tendon. Connect Tissue Res 46: 175–183.

16. TashiroT, HiraokaH, IkedaY, OhnukiT, SuzukiR, et al. (2006) Effect of GDF-5 on ligament healing. J Orthop Res 24: 71–79.

17. PolinkovskyA, RobinNH, ThomasJT, IronsM, LynnA, et al. (1997) Mutations in CDMP1 cause autosomal dominant brachydactyly type C. Nat Genet 17: 18–19.

18. ThomasJT, KilpatrickMW, LinK, ErlacherL, LembessisP, et al. (1997) Disruption of human limb morphogenesis by a dominant negative mutation in CDMP1. Nat Genet 17: 58–64.

19. ThomasJT, LinK, NandedkarM, CamargoM, CervenkaJ, et al. (1996) A human chondrodysplasia due to a mutation in a TGF-β superfamily member. Nat Genet 12: 315–317.

20. YangW, CaoL, LiuW, JiangL, SunM, et al. (2008) Novel point mutations in GDF5 associated with two distinct limb malformations in Chinese: brachydactyly type C and proximal symphalangism. J Hum Genet 53: 368–374.

21. StormEE, HuynhTV, CopelandNG, JenkinsNA, KingsleyDM, et al. (1994) Limb alterations in brachypodism mice due to mutations in a new member of the TGF β-superfamily. Nature 368: 639–643.

22. DaansM, LuytenFP, LoriesRJ (2011) GDF5 deficiency in mice is associated with instability-driven joint damage, gait and subchondral bone changes. Ann Rheum Dis 70: 208–213.

23. ReynardLN, BuiC, Canty-LairdEG, YoungDA, LoughlinJ (2011) Expression of the osteoarthritis-associated gene GDF5 is modulated epigenetically by DNA methylation. Hum Mol Genet 20: 3450–3460.

24. KingsleyC, WinotoA (1992) Cloning of GT box-binding proteins: a novel Sp1 multigene family regulating T-cell receptor gene expression. Mol Cell Bio 12: 4251–4261.

25. KaczynskiJ, CookT, UrrutiaR (2003) Sp1- and Kruppel-like transcription factors. Genome Biol 4: 206–214.

26. ZaidA, HodnyZ, LiR, NelsonBD (2001) Sp1 acts as a repressor of the human adenine nucleotide translocase-2 (ANT2) promoter. Eur J Bioch 268: 5497–5503.

27. ZhangY, DufauML (2003) Repression of the luteinizing hormone receptor gene promoter by cross talk among EAR3/COUP-TFI, Sp1/Sp3, and TFIIB. Mol Cell Biol 23: 6958–6972.

28. MajelloB, De LucaP, LaniaL (1997) Sp3 is a bifunctional transcription regulator with modular independent activation and repression domains. J Biol Chem 272: 4021–4026.

29. ZhangX, LiY, DaiC, YangJ, MundelP, et al. (2003) Sp1 and Sp3 transcription factors synergistically regulate HGF receptor gene expression in kidney. Am J Physiol 284: 82–94.

30. PughBF, TjianR (1991) Transcription from a TATA-less promoter requires a multisubunit TFIID complex. Genes Dev 5: 1935–1945.

31. PascalE, TjianR (1991) Different activation domains of Sp1 govern formation of multimers and mediate transcriptional synergism. Genes Dev 5: 1646–1656.

32. DoetzlhoferA, RothenederH, LaggerG, KorandaM, KurtevV, et al. (1999) Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 19: 5504–5511.

33. KrügerI, VollmerM, SimmonsD, ElsässerHP, PhilipsenS, et al. (2007) Sp1/Sp3 compound heterozygous mice are not viable: Impaired erythropoiesis and severe placental defects. Dev Dyn 236: 2235–2244.

34. BeauchefG, BigotN, KypriotouM, RenardE, PoreeBT, et al. (2012) The p65 subunit of NF-kB inhibits COL1A1 gene transcription in human dermal and scleroderma fibroblasts through its recruitment on promoter by protein interaction with transcriptional activators (c-Krox, Sp1, and Sp3). J Biol Chem 287: 3462–3478.

35. ZhangY, HassanMQ, XieRL, HawseJR, SpelsbergTC, et al. (2009) Co-stimulation of the bone-related Runx2 P1 promoter in mesenchymal cells by SP1 and ETS transcription factors at polymorphic purine-rich DNA sequences (Y-repeats). J Biol Chem 284: 3125–3135.

36. Piera-VelazquezS, HawkinsDF, WhitecavageMK, ColterDC, StokesDG, et al. (2007) Regulation of the human SOX9 promoter by Sp1 and CREB. Exp Cell Res 313: 1069–1079.

37. ConesaC, AckerJ (2010) Sub1/PC4 a chromatin associated protein with multiple functions in transcription. RNA Biol 7: 287–290.

38. GeH, RoederRG (1994) Purification, cloning, and characterization of a human coactivator, PC4, that mediates transcriptional activation of class II genes. Cell 78: 513–523.

39. GeH, SiY, WolffeAP (1998) A novel transcriptional coactivator, p52, functionally interacts with the essential splicing factor ASF/SF2. Mol Cell 2: 751–759.

40. LiaoM, ZhangY, KangJH, DufauML (2011) Coactivator function of positive cofactor 4 (PC4) in Sp1-directed luteinizing hormone receptor (LHR) gene transcription. J Biol Chem 286: 7681–7691.

41. MalikS, GuermahM, RoederRG (1998) A dynamic model for PC4 coactivator function in RNA polymerase II transcription. Proc Natl Acad Sci USA 95: 2192–2197.

42. HuggenvikJI, MichelsonRJ, CollardMW, ZiembaAJ, GurleyP, et al. (1998) Characterization of a nuclear deformed epidermal autoregulatory factor-1 (DEAF-1)-related (NUDR) transcriptional regulator protein. Mol Endocrinol 12: 1619–1639.

43. LemondeS, TureckiG, BakishD, DuL, HrdinaPD, et al. (2003) Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 23: 8788–8799.

44. CzesakM, LemondeS, PetersonEA, RogaevaA, AlbertPR (2006) Cell-specific repressor or enhancer activities of Deaf-1 at a serotonin 1A receptor gene polymorphism. J Neurosci 26: 1864–1871.

45. HahmK, SumEY, FujiwaraY, LindemanGJ, VisvaderJE, et al. (2004) Defective neural tube closure and anteroposterior patterning in mice lacking the LIM protein LMO4 or its interacting partner Deaf-1. Mol Cell Biol 24: 2074–2082.

46. DoddAW, SyddallCM, LoughlinJ (2012) A rare variant in the osteoarthritis-associated locus GDF5 is functional and reveals a site that can be manipulated to modulate GDF5 expression. Eur J Hum Genetics (in press) doi: 10.1038/ejhg.2012.197

47. LescuyerP, MartinezP, LunardiJ (2002) YY1 and Sp1 activate transcription of the human NDUFS8 gene encoding the mitochondrial complex I TYKY subunit. Biochim Biophys Acta 1574: 164–174.

48. DaiJ, ShiD, ZhuP, QinJ, NiH, et al. (2008) Association of a single nucleotide polymorphism in growth differentiate factor 5 with congenital dysplasia of the hip: a case-control study. Arthritis Res Ther 10: R126.

49. PosthumusM, CollinsM, CookJ, HandleyCJ, RibbansWJ, et al. (2010) Components of the transforming growth factor-β family and the pathogenesis of human Achilles tendon pathology-a genetic association study. Rheumatology (Oxford) 49: 2090–2097.

50. WilliamsFMK, PophamM, HartDJ, de SchepperE, Bierma-ZeinstraS, et al. (2011) GDF5 single-nucleotide polymorphism rs143383 is associated with lumbar disc degeneration in Northern European women. Arthritis Rheum 63: 708–712.

51. SannaS, JacksonAU, NagarajaR, WillerCJ, ChenWM, et al. (2008) Common variants in the GDF5-UQCC region are associated with variation in human height. Nat Genet 40: 198–203.

52. VaesRBA, RivadeneiraF, KerkhofJM, HofmanA, PolsHAP, et al. (2008) Genetic variation in the GDF5 region is associated with osteoarthritis, height, hip axis length and fracture risk: the Rotterdam study. Ann Rheum Dis 68: 1754–1760.

53. BrennanP, DonevR, HewamanaS (2008) Targeting transcription factors for therapeutic benefit. Mol BioSyst 4: 909–919.

54. BorgattiM, BoydDD, LamprontiI, BianchiN, FabbriE, et al. (2005) Decoy molecules based on PNA-DNA chimeras and targeting Sp1 transcription factors inhibit the activity of urokinase-type plasminogen activator receptor (uPAR) promoter. Oncol Res 15: 373–383.

55. RowanAD, KoshyPJ, ShingletonWD, DegnanBA, HeathJK, et al. (2001) Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum 44: 1620–1632.

56. ReedDE, HuangXM, WohlschlegelJA, LevineMS, SengerK (2008) DEAF-1 regulates immunity gene expression in Drosophila. Proc Natl Acad Sci USA 105: 8351–8356.

57. Vivancos PD, DriscollSP, BulmanCA, YingL, EmamiK (2011) Perturbations of amino acid metabolism associated with glyphosate-dependent inhibition of shikimic acid metabolism affect cellular redox homeostasis and alter the abundance of proteins involved in photosynthesis and photorespiration. Plant Physiol 157: 256–268.

58. YipL, SuL, ShengD, ChangP, AtkinsonM, et al. (2009) Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Nat Immunol 10: 1026–1033.